Related references
Note: Only part of the references are listed.Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
Katrina Wilcox Hagberg et al.
CLINICAL EPIDEMIOLOGY (2020)
Psoriasis: Which therapy for which patient Focus on special populations and chronic infections
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Trial of Apremilast for Oral Ulcers in Behcet's Syndrome
Guelen Hatemi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
Bintou Ahmadou Ahidjo et al.
EBIOMEDICINE (2016)
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers
Yong Liu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
P. H. Schafer et al.
CELLULAR SIGNALLING (2014)
Share Paper
